Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879125 | 0.80 | PDE4A (0.43) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6817366 | 0.80 | PDE4A (0.43) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8967965 | 0.76 | LMNA (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL31542046 | 0.76 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11870178 | 0.74 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Zinc Ion SCHEMBL14920928 | 0.74 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6129267 | 0.74 | LMNA (0.40) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11501996 | 0.73 | LMNA (0.47) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6668472 | 0.73 | LMNA (0.47) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Potassium Ion SCHEMBL11501588 | 0.73 | LMNA (0.42) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227789-B1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | PROCTER & GAMBLE (US) | 2004-09-22 | — | — | EP | claimed |
| US-6521216-B1 | Dentifrices comprising mixtures of stannous fluoride, chloride and sodium gluconate used as microbiocides and to prevent oral diseases and plaque | THE PROCTER & GAMBLE COMPANY | 2003-02-18 | — | — | US | claimed |
| EP-1227789-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-07 | — | — | EP | claimed |
| WO-2001034109-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1227789-B1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | PROCTER & GAMBLE (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1227789-B1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | PROCTER & GAMBLE (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6521216-B1 | Dentifrices comprising mixtures of stannous fluoride, chloride and sodium gluconate used as microbiocides and to prevent oral diseases and plaque | THE PROCTER & GAMBLE COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6521216-B1 | Dentifrices comprising mixtures of stannous fluoride, chloride and sodium gluconate used as microbiocides and to prevent oral diseases and plaque | THE PROCTER & GAMBLE COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-1227789-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227789-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034109-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034109-A1 | IMPROVED DUAL PHASE STANNOUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |